Study of Novel Types of Familial Diabetes Insipidus

This study is ongoing, but not recruiting participants.

First Received: October 18, 1999 Last Updated: February 21, 2006 History of Changes

Sponsors and Collaborators:	National Center for Research Resources (NCRR) Northwestern University
Information provided by:	Office of Rare Diseases (ORD)
ClinicalTrials.gov Identifier:	NCT00004364

Purpose

OBJECTIVES:

I. Define the phenotype and genotype of previously unrecognized types of familial diabetes insipidus (FDI) in kindreds with atypical or novel forms of FDI.

Condition	Intervention
Diabetes Insipidus	Drug: desmopressin

MedlinePlus related topics: Diabetes Diabetes Insipidus Diabetes Medicines

Drug Information available for: Desmopressin

U.S. FDA Resources

Study Type:	Observational
Study Design:	Screening

Further study details as provided by Office of Rare Diseases (ORD):

Estimated Enrollment:	5
Study Start Date:	December 1995

Detailed Description:

PROTOCOL OUTLINE: Participants undergo a series of tests to determine the presence, absence, cause, natural history, clinical status, and mode of inheritance of their type of diabetes insipidus (DI). The studies include measurements of basal fluid intake and urine output, plasma vasopressin during standard fluid deprivation or waterload/saline infusion tests, and changes in water balance during a therapeutic trial of DDAVP. If clinically indicated, echocardiograms and assays of plasma catecholes and renin are also completed.

Linkage analysis is performed for all participants; kindreds with the Marfan-like syndrome are also studied for the fibrillin-1 genotype.

Participants determined to have DI are treated with desmopressin for 2 days.

Eligibility

Ages Eligible for Study:	6 Months to 70 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Familial diabetes insipidus (DI) in atypical or novel form, e.g.: Dipsogenic DI Neurohypophyseal DI
Affected and unaffected members of kindreds eligible

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00004364

Sponsors and Collaborators

National Center for Research Resources (NCRR)

Northwestern University

Investigators

Study Chair:

Gary L. Robertson

Northwestern University

More Information

No publications provided

Study ID Numbers:	199/11939, NU-570
Study First Received:	October 18, 1999
Last Updated:	February 21, 2006
ClinicalTrials.gov Identifier:	NCT00004364 History of Changes
Health Authority:	United States: Federal Government

Keywords provided by Office of Rare Diseases (ORD):

diabetes insipidus
endocrine disorders
rare disease

Study placed in the following topic categories:

Metabolic Diseases
Pituitary Diseases
Diabetes Mellitus
Rare Diseases
Endocrine System Diseases
Cardiovascular Agents
Hemostatics
Arginine Vasopressin

Urologic Diseases
Diabetes Insipidus
Deamino Arginine Vasopressin
Vasopressins
Kidney Diseases
Endocrinopathy
Glucose Metabolism Disorders
Metabolic Disorder

Additional relevant MeSH terms:

Metabolic Diseases
Coagulants
Pituitary Diseases
Hematologic Agents
Physiological Effects of Drugs
Diabetes Mellitus
Endocrine System Diseases
Cardiovascular Agents
Hemostatics

Pharmacologic Actions
Urologic Diseases
Diabetes Insipidus
Natriuretic Agents
Therapeutic Uses
Deamino Arginine Vasopressin
Kidney Diseases
Glucose Metabolism Disorders
Antidiuretic Agents

ClinicalTrials.gov processed this record on May 07, 2009